文献速递创伤骨科关节外科

口服直接Xa因子抑制剂对急性股骨颈骨折关节置换术后髋关节异位骨化发生率的影响:倾向评分匹配队列研究

Effect of Oral Direct Factor Xa Inhibitors on the Prevalence of Hip Heterotopic Ossification Following Arthroplasty for Acute Femoral Neck Fracture: A Propensity Score-matched Cohort Study.
PubMed 文献 · J Arthroplasty · 2025-09-04

这项在上海国家骨科中心开展的回顾性倾向评分匹配队列研究(2019-2023年)纳入944例因急性股骨颈骨折行髋关节置换术的患者,经1:1匹配后每组362例。结果显示,使用口服直接Xa因子抑制剂与异位骨化发生率升高相关(29.2% vs 15.7%,OR 2.22,95%CI 1.55-3.20,P<0.001),临床重要异位骨化风险亦升高(OR 3.29,95%CI 1.59-7.48,P=0.002)。作者认为直接Xa因子抑制剂使用可能是术后异位骨化形成的新危险因素。

要点

  • 匹配后使用Xa因子抑制剂组异位骨化发生率为29.2%,未使用组为15.7%。
  • 使用Xa因子抑制剂与异位骨化风险升高相关(OR 2.22,95%CI 1.55-3.20,P<0.001)。
  • 使用Xa因子抑制剂与临床重要异位骨化风险升高相关(OR 3.29,95%CI 1.59-7.48,P=0.002)。

核心结论

  • 直接Xa因子抑制剂使用可能是急性股骨颈骨折髋关节置换术后异位骨化形成的新危险因素。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,在上海一家国家骨科中心开展,时间范围为2019年至2023年。
  • 共评估944例因急性股骨颈骨折行髋关节置换术的患者,经排除和1:1匹配(性别、年龄、体重指数、受伤侧、非甾体抗炎药使用)后,Xa因子抑制剂组和无Xa因子抑制剂组各纳入362例。
  • 所有患者住院期间均接受低分子量肝素,未使用其他抗凝药。

主要发现

  • 在倾向评分匹配人群中,异位骨化发生率在Xa因子抑制剂组为29.2%,在无Xa因子抑制剂组为15.7%。
  • 临床重要异位骨化发生率在Xa因子抑制剂组为7.7%,在无Xa因子抑制剂组为2.4%。
  • 逻辑回归分析显示,与未使用相比,Xa因子抑制剂使用与更高的异位骨化率显著相关(比值比2.22;95%置信区间1.55至3.20;P<0.001)。
  • Xa因子抑制剂使用还与临床显著异位骨化风险升高相关(比值比3.29;95%置信区间1.59至7.48;P=0.002)。
  • 基线协变量均未对Xa因子抑制剂使用与异位骨化发生率之间的关联产生显著影响(所有P>0.05),敏感性分析进一步证实了这些结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heterotopic ossification (HO) is a common complication following hip arthroplasty that can limit hip range of motion. Oral direct factor Xa (FXa) inhibitors are commonly used anticoagulants after arthroplasty; however, they have a high risk of local bleeding and hematoma formation, which are significant triggers for HO formation. To our knowledge, there is no evidence regarding whether FXa inhibitors use will increase HO incidence following hip arthroplasty. METHODS: In this retrospective propensity score-matched cohort study conducted at a national orthopaedic center in Shanghai (2019-2023), 944 patients undergoing hip arthroplasty for acute femoral neck fracture were evaluated. After exclusions and 1:1 matching (sex, age, body mass index, injury side, nonsteroidal anti-inflammatory drugs use), 362 patients were included in each group (FXa inhibitors vs. no FXa inhibitors). All patients received low-molecular-weight heparin during hospitalization and no other anticoagulants. RESULTS: In the propensity score-matched population, the incidence of HO was 29.2% in the FXa inhibitors group and 15.7% in the no-FXa inhibitors group (7.7% and 2.4% for clinically important HO, respectively). Logistic regression analyses revealed that FXa inhibitors usage was significantly associated with a higher rate of HO (odds ratio, 2.22; 95% confidence interval, 1.55 to 3.20; P < 0.001) compared to no usage. Additionally, FXa inhibitors use was also linked to an increased risk of clinically significant HO (odds ratio, 3.29; 95% confidence interval, 1.59 to 7.48; P = 0.002). None of the baseline covariates demonstrated a significant influence on the association between FXa inhibitors use and HO incidence (P > 0.05 for all). Sensitivity analyses further corroborated these results. CONCLUSIONS: Direct FXa inhibitors use may be a new risk factor of HO development following hip arthroplasty for acute femoral neck fracture. LEVEL OF EVIDENCE: Therapeutic Level II.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Chen Z, Xu Y, Liu H, et al. Effect of Oral Direct Factor Xa Inhibitors on the Prevalence of Hip Heterotopic Ossification Following Arthroplasty for Acute Femoral Neck Fracture: A Propensity Score-matched Cohort Study. J Arthroplasty. 2025. PMID: 40912338. doi:10.1016/j.arth.2025.08.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。